S
Samuel J. Bonacorsi
Researcher at Bristol-Myers Squibb
Publications - 81
Citations - 2102
Samuel J. Bonacorsi is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Metabolite & Pharmacokinetics. The author has an hindex of 17, co-authored 78 publications receiving 1759 citations. Previous affiliations of Samuel J. Bonacorsi include Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan,Charles Frost,Zhigang Yu,Kan He,Haiying Zhang,W. Griffith Humphreys,Donald J. P. Pinto,Shiang-Yuan Chen,Samuel J. Bonacorsi,Pancras C. Wong,Donglu Zhang +10 more
TL;DR: Apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metabolism and renal excretion with no serious adverse events or discontinuations due to adverse effects.
Journal ArticleDOI
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
Anna-Larissa N. Niemeijer,David Leung,Marc C. Huisman,Idris Bahce,Otto S. Hoekstra,G.A.M.S. (Guus) van Dongen,Ronald Boellaard,Shuyan Du,Wendy Hayes,Ralph Adam Smith,Albert D. Windhorst,N.H. Hendrikse,Alex J. Poot,Danielle J. Vugts,Erik Thunnissen,Paul E. Morin,Dasa Lipovsek,David J. Donnelly,Samuel J. Bonacorsi,Linda M. Velasquez,T.D. de Gruijl,Egbert F. Smit,A.J. de Langen,A.J. de Langen +23 more
TL;DR: The authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy and show it correlates with response.
Journal ArticleDOI
Metabolism and disposition of dasatinib after oral administration to humans.
Lisa J. Christopher,Donghui Cui,Chiyuan Wu,Roger T. Luo,James Manning,Samuel J. Bonacorsi,Michael W. Lago,Alban Allentoff,Francis Y. Lee,Betty McCann,Susan Galbraith,Donald P. Reitberg,Kan He,Anthony Barros,Anne Blackwood-Chirchir,W. Griffith Humphreys,Ramaswamy A. Iyer +16 more
TL;DR: The exposures of pharmacologically active metabolites M4, M5, M6, M20, and M24 in patients, along with their cell-based IC50 for Src and Bcr-Abl kinase inhibition, suggested that these metabolites were not expected to contribute significantly toward in vivo activity.
Journal ArticleDOI
Pd(II)-catalyzed C-H iodination using molecular I2 as the sole oxidant.
TL;DR: Pd-catalyzed ortho-C-H iodination directed by a weakly coordinating amide auxiliary using I2 as the sole oxidant was developed, compatible with a wide range of heterocycles.
Journal ArticleDOI
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly,R. Adam Smith,Paul E. Morin,Dasa Lipovsek,Jochem Gokemeijer,Daniel Cohen,Virginie Lafont,Tritin Tran,Erin L. Cole,Martin C. Wright,Joonyoung Kim,Adrienne Pena,Daniel W. Kukral,Douglas D. Dischino,Patrick L Chow,Jinping Gan,Olufemi Adelakun,Xi-Tao Wang,Kai Cao,David Leung,Samuel J. Bonacorsi,Wendy Hayes +21 more
TL;DR: The feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies is demonstrated by 18F-BMS-986192, which bound to tumor tissues as a function of PD- L1 expression determined by immunohistochemistry.